Canada-based medical device company Vielight has reported positive outcomes of a pilot study of its Vielight 810 Infrared and patent-pending Vielight Neuro wearable devices to treat Alzheimer's disease (AD) or dementia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The randomised, placebo-controlled trial involved 19 patients who were treated with Neuro over a duration of 20 minutes once or twice a week and the Vielight 810 for 25 minutes every day.
The devices are based on technologies involving the low-level light therapy (LLLT) or photobiomodulation therapy (PBMT).
PBMT is a process which has a low-level exposure to light or light emitting diodes which triggers cellular function resulting in beneficial clinical effects.
The results of the pilot study have demonstrated that the treatment for people with moderate-severe cognitive impairment can result in clinical improvements.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVielight CEO and inventor Lew Lim said: "The promise shown in this pilot study is owed to decades of work by numerous researchers in the field of photobiomodulation.
“We are privileged to be able to translate the research into wearable devices that have shown such encouraging results.
“This has provided a good basis for us to progress to a more rigorous clinical trial; and we aim to start the process in the next few months with the support of MaRS EXCITE."
Vielight will be assisted by the MaRS Excellence in Clinical Innovation Technology Evaluation (EXCITE) programme in implementing the device in Canada, US and the UK to treat memory and cognitive decline in patients suffering from dementia and Alzheimer's disease.
Image: View of Vielight Neuro to treat Alzheimer's disease. Photo: courtesy of PRNewsFoto / VieLights.
